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The National Tuberculosis Genotyping and Surveillance Network was established in 1996 to perform a 5-
year, prospective study of the usefulness of genotyping Mycobacterium tuberculosis isolates to tuberculo-
sis control programs. Seven sentinel sites identified all new cases of tuberculosis, collected information on
patients and contacts, and obtained patient isolates. Seven genotyping laboratories performed DNA finger-
printing analysis by the international standard IS6110 method. BioImage Whole Band Analyzer software
was used to analyze patterns, and distinct patterns were assigned unique designations. Isolates with six or
fewer bands on IS6110 patterns were also spoligotyped. Patient data and genotyping designations were
entered in a relational database and merged with selected variables from the national surveillance data-
base. In two related databases, we compiled the results of routine contact investigations and the results of
investigations of the relationships of patients who had isolates with matching genotypes. We describe the
methods used in the study.
olecular characterization of strains of Mycobacterium
tuberculosis has been used for more than a decade to
study the epidemiology of tuberculosis (TB). DNA finger-
printing, with IS6110 as a probe, has been used successfully to
trace transmission of M. tuberculosis in outbreaks, confirm
laboratory cross-contamination, and identify risk factors for
disease among populations of patients with TB (1). Before
1993, epidemiologic studies that used molecular characteriza-
tion of M. tuberculosis were focused on populations, such as
persons who were HIV positive or were in nosocomial settings
(2–4). The standardization of methods provided an opportunity
to examine M. tuberculosis strains from TB patients through-
out the world and encompassed a variety of settings and popu-
lations (5).
In response to the upsurge of TB cases in the United States,
the Centers for Disease Control and Prevention (CDC) funded
regional laboratories to provide fingerprinting services to sup-
port TB control programs in outbreak investigations and to
conduct studies on using DNA fingerprinting in TB epidemiol-
ogy and control. This network was expanded to include senti-
nel surveillance sampling in 1996, when CDC established the
National Tuberculosis Genotyping and Surveillance Network
as a 5-year project. The genotyping network involved seven
sentinel surveillance sites1 that were paired with seven geno-
typing laboratories.2 The historical background and objectives
of the genotyping network have been discussed elsewhere (6).
In this paper, we summarize the specific project methods. 
Network Participants
The sentinel surveillance sites included the states of
Arkansas, Maryland, Massachusetts, Michigan, and New Jer-
sey; six counties in California surrounding San Francisco
(Alameda, Contra Costa, Marin, San Mateo, Santa Clara, and
Solano); and four counties in Texas representing two regions
of the state with distinct demographics (Dallas, Tarrant, Cam-
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1Sentinel surveillance sites and personnel: 1) Arkansas Department of Health:
Joseph Bates, Donald Cunningham, Kashef Ijaz, Bill Starrett, William Stead, and
Frank Wilson; 2) California Department of Health Services: Rocio Agraz, Dan
Chin, Jennifer Flood, Peter Oh, Sarah Royce, and Sumi Sun; 3) Maryland Depart-
ment of Health and Mental Hygiene: Wendy Cronin, Jonathan Golub, David
Hooper, Nancy Hooper, Monica Lathan, Leonard Mukasa, and Jafar Razeq; 4)
Massachusetts Department of Public Health: Edward Corkren, Paul Elvin, Sue
Etkind, Ann Miller, Edward Nardell, Jill Northrup, Alissa Scharf, Sharon Sharnpra-
pai, Alexander Sloutsky, Robert Suruki, and Debra Thimas; 5) Michigan Depart-
ment of Community Health: Bernie Benecke, Matthew Boulton, Norm Keon,
Michael Kucab, Dennis Minnice, Jolynn Montgomery, and Charles Williams II; 6)
New Jersey Department of Health and Senior Services: Nancy Buono, Mary Dil-
lon, Zary Liu, Marcia Localio, Christian Nwigwe, Felicidad Santos, Mary Ellen
Schulman, and Kenneth Shilkret; 7) Texas Department of Health: Dennis Ash-
worth, Dale Dingley Jr., Miguel Garza, Jeff Taylor, and Patricia Thickstun.
2Genotyping laboratories and personnel: 1) Alabama Department of Public Health
and University of Alabama, Birmingham: William Benjamin Jr., Nancy Dunlap,
Donna Hafner, Nancy Keenan, Kerry Lok, Donna Mulcahy, Virginia Pruitt, and
Nancy Robinson; 2) Central Arkansas Veterans Healthcare Services: M. Donald
Cave, Kathleen Eisenach, Ndingsa Fomukong, and ZhenhuaYang; 3) California
Department of Health Services: Jason Coloma, Jonna De Leon, Edward Des-
mond, Athena Fye, Marguerite Griffith, Melvin Javonillo, Travis Jobe, Rose Longo-
ria, Cynthia Sanders, and Lourdes Seli; 4) Michigan Department of Community
Health: Dale Berry, Steve Church, Stephen Dietrich, Frances Pouch Downes, Jef-
frey Massey, Teresa Miller, Laura Mosher, and Patricia Somsel; 5) New York State
Health Department,Wadsworth Center: Jeff Driscoll, Robert Jovall, Mike McGarry,
Max Salfinger, and Harry Taber; 6) Public Health Research Institute, New York:
Pablo Bifani, Barry Kreiswirth, Natalia Kurepina, Barun Mathema, Soraya Mog-
hazeh, Alex Ravikovitch, and Elena Shashkina; and 7) Texas Center for Infectious
Diseases: Yvonne Camarce, Rebecca Cox, J. Seb Gillette, Oscar Gonzalez, Ken-
neth Jost, D. Mitch Magee, Teresa Quitugua, Ishmael I. Rosas, and Jeffery Taylor.
M
Dr. Crawford is chief of the Immunology and Molecular
Pathogenesis Section, Tuberculosis/Mycobacteriol-
ogy Branch, Division of AIDS, STD, and TB Laboratory
Research, Centers for Disease Control and Preven-
tion. His research interests include application of
molecular methods to epidemiology and diagnostics of
mycobacterial diseases.
Jack T. Crawford, 
Guest EditorEmerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1193
TUBERCULOSIS GENOTYPING NETWORK
eron, and Hidalgo) (Figure). State departments of health TB-
control programs conducted the project activities for each site.
The seven laboratories provided DNA fingerprint analyses of
M. tuberculosis isolates for their sentinel surveillance sites. In
addition, genotyping network laboratories were assigned
regions for which they provided genotype analysis of M.
tuberculosis isolates in support of investigations by state
departments of health. These isolates and associated patients
were not included in the network databases. Regions were
delineated on the basis of the approximate number of patients
with TB in the regions; regions did not follow the boundaries
of the U.S. Public Health Service Regions. 
Case Finding and Isolate Collection
Sources of information to identify TB cases within surveil-
lance sites included hospital and clinic records from all facili-
ties serving patients in the area, records of laboratories
performing mycobacteriology services, hospital ICD-9CM
discharge codes for TB, pharmacy records for prescriptions of
anti-TB drugs, medical examiners’ or coroners’ records, death
certificates, and AIDS surveillance reports that listed a diagno-
sis of TB. Culture-positive, verified TB cases reported from
January 1996 through December 2000 for national TB surveil-
lance to CDC (reported on the Report of a Verified Case of
Tuberculosis) were included as sentinel surveillance cases.
Patients with recurrent TB occurring >1 year after completion
of therapy are considered new case-patients; a small number of
such cases were included. Patients later identified as residing
outside of the surveillance area and those with positive cul-
tures as the result of laboratory cross-contamination were
excluded. 
Every effort was made to acquire an isolate from each
study patient. This task was difficult because many clinical
samples were sent for culturing to laboratories other than the
state public health laboratory, including hospital and commer-
cial laboratories, some out of state. Isolates identified as M.
tuberculosis complex, i.e., M. tuberculosis, M. bovis, and M.
africanum, were included in the study. Isolates were sent to the
assigned genotyping laboratory for typing. Stocks of all iso-
lates were maintained at –70°C, and all isolates were trans-
ferred to CDC for long-term storage and future studies. 
Laboratory Protocols
All National Tuberculosis Genotyping and Surveillance
Network laboratories used standardized protocols. Isolates
were typed by the international standard IS6110 method, i.e.,
digestion of DNA with endonuclease PvuII and hybridization
with a probe containing the right end of IS6110 (5). Growth
was harvested directly from Lowenstein-Jensen slants, or iso-
lates were subcultured in Middlebrook 7H9 broth. Cell sus-
pensions were heat-killed before DNA was extracted. DNA
was digested with PvuII and run on a 20-cm, 1% agarose gel
without ethidium bromide. Electrophoresis was conducted at
100 V for a short time to allow the DNA to enter the gel and
then overnight at lower voltage until the dye front had run
approximately 17 cm. An external size standard was run in
wells 1, 10, and 20 on a 20-well gel. The gel was stained with
ethidium bromide and photographed on a UV transilluminator
to check for quality, including complete digestion of the DNA
samples, degradation of DNA, and uneven running or smiling
of the gel. Gels were blotted and hybridized in the standard
fashion with chemiluminescent probes (ECL kit, Amersham
Biosciences, Piscataway, NJ) and x-ray film, with the excep-
tion of one laboratory that used 32P-labeled probes and a phos-
phoimager to generate direct digital images. 
Two different size standards were used. Initially, total
genomic DNA from M. tuberculosis strain 2650, provided by
the genotyping laboratory at the Public Health Research Insti-
tute, New York, was used. This standard was replaced by a
recombinant size standard prepared at CDC; this standard con-
tains 25 fragments of known sequences, ranging in size from
700 to 15,000 bp. All fragments contain at least one copy of a
500-bp segment of the right side of IS6110 and are detected by
the IS6110 probe. When the recombinant standard was avail-
able, the sizes of the fragments in the original 2650 standard
were determined relative to the new standard, and these sizes
were used to reanalyze all of the prior images containing the
2650 standard. 
Computer-Assisted Pattern Analysis
IS6110 patterns were scanned and then analyzed by
regional laboratory personnel by using BioImage Whole Band
Analyzer software, version 3.4 (BioImage, Ann Arbor, MI), a
UNIX-based program run on Sun workstations (Sun Microsys-
tems, Inc., Santa Clara, CA). This version of the software
included enhancements developed specifically for the TB
genotyping network. The software performed automatic band
identification, but each image was visually evaluated and
edited, as needed. The greatest difficulty was deciding if bands
of greater than average width or intensity represented single or
multiple fragments. The protocol called for assigning multiple
bands only when separate bands were clearly evident, which
often required observation of multiple exposures of the origi-
nal films. Bands with lower than average intensity were
counted only if the peak height in the scanned image was at
least two thirds that of adjacent bands. The logarithmic scale
method was used to size bands. 
Figure. Map showing locations of the sentinel surveillance sites in the
National Tuberculosis Genotyping and Surveillance Network, United
States.TUBERCULOSIS GENOTYPING NETWORK
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For pattern matching, BioImage software used the Jaccard
coefficient of similarity between two patterns, A and B (100 x
number of matched bands [number of bands in A + number of
bands in B – number of matched bands]). Pairs of patterns
were compared for matching bands by a deviation of ±2.5%
for molecular weight (not distance migrated). All matches
were verified by visual comparisons. Only patterns that were
identical, i.e., had the same number of bands of the same sizes
(±2.5%), were given the same designation.
Each regional laboratory maintained a database of finger-
print patterns for all isolates from the laboratory’s sentinel site.
New patterns were submitted to CDC for assignment of a
genotyping network database designation. Any subsequent
isolates with the identical fingerprint pattern were assigned the
same designation and were not submitted to CDC. Files of sin-
gle gel lanes were transmitted to a secure site at CDC. These
files contained the original scanned image and the data file of
calculated band sizes. In these images, bands included in the
analysis were highlighted, and the locations of the bands in the
standard were indicated. The database manager examined the
images to determine if they were of acceptable quality but did
not make changes in the submitted files. Apparent discrepan-
cies were referred to the submitting laboratory for resolution,
and the final decision about band identification rested with the
laboratory that performed the analysis and had the original
films. Submitted patterns were compared to the patterns in the
existing TB genotyping network database by using the param-
eters described above. New patterns were added to the data-
base and assigned consecutive 5-digit designations. When a
submitted pattern matched a pattern already in the database,
the submitted pattern was reported back with the existing des-
ignation. Thus, the TB genotyping network fingerprint data-
base contained single examples of all distinct patterns from all
seven regional laboratories during the 5-year study period. The
designation 00000 was assigned to isolates having zero copies
of IS6110, i.e., gave no bands. Some patterns were dropped
from the study, e.g., if the isolate was the result of cross-con-
tamination or the patient was from outside the study area.
These designations were not reused; therefore, the total num-
ber of patterns (6,128) in the final database is lower than the
highest designation (pattern 07193). 
Secondary Typing
During the early part of the study, polymorphic GC-rich
sequence (PGRS) typing, also referred to as pTBN12 (7), was
used for secondary typing. However, this method was difficult
to standardize, and spoligotyping (spacer oligotyping) was
used for secondary typing (8). Isolates with six or fewer bands
on IS6110 typing, including most isolates that had been typed
previously by using PGRS, were spoligotyped by using a stan-
dard method (9). The spoligotypes were recorded by using a
15-digit octal code to represent the binary result for the 43
spacers (10). Briefly, the 43-digit binary result, representing
the 43 spacers (where 1=positive, 0=negative), was divided
into 14 sets of 3 digits (spacers 1–42) plus 1 additional digit
(spacer 43). Each 3-digit set was converted to octal code
(000=0, 001=1, 010=2, 011=3, 100=4, 101=5, 110=6, and
111=7) with the final digit remaining either 1 or 0. This
scheme yielded a 15-digit octal designation. To simplify data-
base entries, the CDC database manager assigned consecutive
arbitrary 4-digit designations to the octal designations.
Quality Assurance
Several sets of isolates were prepared at CDC and distrib-
uted to the typing laboratories for fingerprinting and analysis.
Their results and results of typing at CDC were analyzed to
determine reproducibility. Because such challenge sets may
receive special handling, a second approach was used in the
final 3 years of the project. For each laboratory, the database
manager selected IS6110 patterns at random from those previ-
ously submitted by that laboratory to the CDC database. The
corresponding isolates, 10 per year per laboratory, were sent to
CDC for typing, and results were compared to prior patterns.
Epidemiologic Databases
Sentinel surveillance sites each maintained a database of
their patients and patient isolate genotype designations in Epi-
Info 6.04d software (case file) (11). Patients were identified by
their state surveillance case numbers. Complete files from
each sentinel site were transmitted to CDC on a bimonthly
basis and concatenated. These data were merged with select
variables from the national TB surveillance database (SURVS-
TB and TIMS) in an SAS dataset (SAS Institute, Inc., Cary,
NC).
For each sentinel surveillance patient, data were collected
concerning any TB case-patients identified as epidemiologi-
cally related through routine contact investigations conducted
as part of TB-control programs. Epidemiologic connections
were defined as direct exposure to an infectious TB patient
(e.g., named contacts) or a circumstance in which patients
were in the same location at the same time (e.g., the same jail).
Related cases identified though routine contact investigations
were included in the study if they had been diagnosed on or
after January 1, 1990. Data collected for each related case-
patient included the following: direction of transmission
(source, secondary); type of relationship (household, non-
household relatives or friends, co-worker, common source);
type of setting of exposure (e.g., correctional facility, school or
day-care center, co-worker, emergency shelter, group quarters,
hospital, nursing home, other long-term care facility); and date
that the epidemiologic relationship was discovered. Informa-
tion for each related case identified through routine contact
investigation was entered into a supplemental Epi-Info file,
which was also routinely submitted to CDC. This database
was merged with the case file data in an SAS dataset.
Genotype Cluster Investigation
Case-patients with isolates demonstrating indistinguish-
able genotypes, i.e., the same IS6110-pattern designation for
isolates with more than six IS6110 bands or the same IS6110Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1195
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pattern and spoligotype for isolates with six or fewer IS6110
bands, were defined as genotype clusters. All cases in clusters
required review of epidemiologic information obtained from
contact investigations before isolate genotyping to determine
known epidemiologic connections. If one or more patients in a
cluster had no known epidemiologic connections with others
in the cluster, a cluster investigation was initiated. Patients par-
ticipated with informed consent. Cluster investigations were
conducted prospectively from January 1, 1998, to December
31, 2000. Data from medical record reviews and interviews
with the patients were collected by using standardized forms.
Information collected from interviews included demographics,
TB medical history, any TB exposures, and at least a 2-year
history for residence and social, work, and recreational activi-
ties. Information collected from medical records and inter-
views was compared for patients in each cluster to identify
epidemiologic connections. The results of cluster investiga-
tions were entered into a third Epi-Info file. This file also con-
tained related positive skin-test results, date of initial skin
tests, direction of transmission, types of relationships, expo-
sure settings, start dates of likely exposure, and information
used to identify relationships (record review, routine interview,
contact investigation, and isolate genotyping information).
Data were submitted to CDC and converted into an SAS
dataset for future analyses.
Weaknesses in Study Design
From the beginning of the project, we recognized that
compiling results from multiple laboratories would be chal-
lenging because of the variability in the IS6110 fingerprinting
method. However, assigning a designation to the IS6110 pat-
tern for each isolate was necessary to allow entry of the result
into the epidemiologic database. Two flaws in the design of the
national fingerprint database were identified during the
project; both primarily affected the analysis of isolates with
low-copy numbers for IS6110. The first flaw arose from the
computer algorithm for pattern matching. A newly submitted
pattern (B) was considered distinct from an existing pattern
(A) if any band in the pattern differed by more than the
allowed 2.5% variation in size. However, a third pattern with a
band of intermediate size can match both A and B. Thus, the
software could identify a set of patterns that matched at 100%,
even though some individual pairs within the set did not
match. The second flaw was procedural. When a laboratory
submitted a pattern that matched one already in the database,
the existing designation was reported back to that laboratory.
In such situations, the submitted image became the reference
in that laboratory’s database for that pattern designation. In
retrospect, we realize that more consistent results would have
been obtained if we had transmitted the prototype image from
the national database to the regional laboratories so that every-
one would have been using the same patterns for matching,
i.e., the same set of band sizes.
Quality assurance results (12) highlighted the need for
experienced judgment in evaluating and editing patterns and
matching results. In addition, isolates with few copies of
IS6110 and common spoligotypes may not be well discrimi-
nated with these genotyping methods. The subjective nature of
genotype interpretation and lack of specificity for some iso-
lates may have resulted in some patients being misclassified as
clustered or not.
Determination of epidemiologic connections based on rou-
tine contact investigations was problematic. Methods used by
different jurisdictions varied considerably, as did the com-
pleteness of contact investigations. Therefore, interpretation
and comparison of the proportion of cases with epidemiologic
connections established by contact investigations among the
sentinel sites should be done with caution. Genotype cluster
investigations proved particularly difficult in several situa-
tions. Though cluster investigations were conducted prospec-
tively, some genotype results were delayed for prolonged
periods. Patients who had completed therapy were often diffi-
cult to locate for interviews. Delay in identifying clusters also
occurred when a prolonged period had elapsed between diag-
noses and cultures of patient specimens; delays also varied
among the sites. The success of identifying epidemiologic
links among clustered patients in these circumstances was lim-
ited.
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